Telix has announced that the first patient has been dosed in an early access program in the Netherlands for its investigational positron emission tomography imaging agent TLX250-CDx in clear cell renal cell carcinoma.
Telix says the first patient dosed in European early access program for TLX250-CDx
December 6, 2023 Australian Biotech
Latest Video
New Stories
-
Medicines Australia backs focus on listings and productivity in government brief
July 3, 2025 - - Latest News -
AusBiotech seeking a head of investment to drive sector growth
July 3, 2025 - - Australian Biotech -
What's the point of pretending that Australia doesn't free-ride on US innovation?
July 3, 2025 - - Latest News -
Framework pushes genomics funding to a review that is mostly silent on it
July 3, 2025 - - Latest News -
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News